Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Phase 2 N=99 Randomized Triple-blind Treatment

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

Bottom Line

View on ClinicalTrials.gov: NCT03776175 ↗
Enrolled (actual)
99
Serious AEs
1.0%
Results posted
Sep 2020
Primary outcome: Primary: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 — 8.14; -40.01; -30.14; -40.13 percent change — p=0.0000

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
PF-05221304 Monotherapy (Drug); PF-06865571 Monotherapy (Drug); Placebo (Drug); PF-05221304 and PF-06865571 Combination (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Pfizer
Primary completion
Sep 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42		 8.14; -40.01; -30.14; -40.13 0.0000 sig
SECONDARY
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)		 3; 10; 10; 10; 0; 0 —
SECONDARY
Number of Participants With Laboratory Abnormalities		 6; 17; 11; 6 —
SECONDARY
Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Blood Pressure		 10.8; 7.0; 9.6; 7.5; 6.1; 3.9 —
SECONDARY
Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Pulse Rate		 7.5; 8.1; 6.8; 6.9; -3.4; -2.9 —
SECONDARY
Number of Participants Meeting Pre-Specified Electrocardiogram (ECG) Criteria		 0; 0; 0; 0; 0; 0 —

Summary

This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD. In addition, this study will evaluate the safety and tolerability of co administration of PF 05221304 and PF 06865571 along with the effects on selected pharmacodynamics (PD)/exploratory parameters, compared to administration of PF 05221304 alone, PF 06865571 alone, and placebo in adults with NAFLD.

Eligibility Criteria

Inclusion Criteria

  • Male subjects or female subjects of non childbearing potential
  • Total body weight of >50 kg (110 lbs) and a BMI greater than or equal to 25 kg/m2
  • Medical diagnosis of Type 2 Diabetes Mellitus (T2DM) being treated with no more than 1 acceptable oral antidiabetic drug OR Subjects without a diagnosis of T2DM that meet 2 or more of the following 5 criteria commonly associated with metabolic syndrome
  • Fasting Plasma Glucose (FPG) greater than or equal to 100 mg/dL;
  • Documentation of at least stage 1 hypertension or medical history of hypertension;
  • Fasting serum HDL C 400 mg/dL;
  • AST, ALT, or GGT >2.0x ULN;
  • Hemoglobin A1c (HbA1c) >7.0%;
  • Fasting plasma glucose >270 mg/dL;
  • Total bilirubin >1.5x ULN;
  • Albumin =160 mmHg and/or diastolic BP>=100 mmHg.
  • Supine 12 lead ECG demonstrating a corrected QT (QTcF) interval >450 msec or a QRS interval >120 msec.
  • Subjects with an estimated GFR <60 mL/min/1.73m2.
  • Evidence or diagnosis of other forms of chronic liver diseases.
  • Subjects with any of the following medical conditions:
  • Any condition possibly affecting drug absorption (eg prior bariatric surgery, gastrectomy, ileal resection);
  • Diagnosis of type 1 diabetes mellitus;
  • History of congestive heart failure, unstable angina, myocardial infarction, stroke, or transient ischemic attack;
  • Any malignancy not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin);
  • Active placement of medical devices in/on thoracic or abdominal cavities such as pacemakers, defibrillators;
  • Subjects with any anatomical or pathological abnormality that would either preclude or tend to confound the analysis of study data.
  • Blood donation of approximately 1 pint or more within 60 days prior to dosing.
  • Subjects taking prohibited concomitant medication(s) or those unwilling/unable to switch to permitted concomitant medication(s)
  • Weight loss of greater than or equal to 5% within 1 month prior to Screening.
  • Unwilling or unable to comply with the Lifestyle Requirements criteria of the protocol.
  • Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential; fertile male subjects who are unwilling or unable to use highly effective method(s) of contraception.
  • Investigator site staff members or Pfizer employees, including their family members, directly involved in the conduct of the study.
  • Subjects with known prior treatment with or participation in a clinical trial involving any of the IPs
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03776175). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search